Mucosal transmission of human immunodeficiency virus

Current HIV Research

Volumn 10, Issue 1, 2012, Pages 3-8

  Tebit, Denis M ^a   Ndembi, Nicaise ^b   Weinberg, Aaron ^c   Quiñones Mateu, Miguel E ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF HUMAN VIROLOGY NIGERIA   (Nigeria)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

HIV; Microbicides; Oral transmission; Sexual transmission

Indexed keywords

AMYLASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BETA DEFENSIN; BETA DEFENSIN 2; BETA DEFENSIN 3; CYTOKINE; LACTOFERRIN; MICROBICIDE; MUCIN; PROLINE RICH PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TENOFOVIR; THROMBOSPONDIN;

ANILINGUS; CD4+ T LYMPHOCYTE; CIRCUMCISION; CLINICAL TRIAL (TOPIC); CONDOM; CYTOKINE PRODUCTION; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION SENSITIVITY; INNATE IMMUNITY; MACROPHAGE; MOUTH MUCOSA; MUCOSA VIRUS TRANSMISSION; NONHUMAN; ORAL HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION; PENIS; PENIS HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION; PREPUCE; PROTEIN EXPRESSION; RECTAL HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION; RECTUM MUCOSA; REVIEW; SALIVA; SEX DIFFERENCE; SEXUAL TRANSMISSION; TRANSCYTOSIS; UTERINE CERVIX EPITHELIUM; VAGINA EPITHELIUM; VAGINA MUCOSA; VAGINAL HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION; VIRION; VIRUS ENTRY; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; MALE; MOUTH MUCOSA; MUCOUS MEMBRANE; PENIS; RECTUM; VAGINA;

EID: 84857131002     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212799304689     Document Type: Review

References (93)

1. Li Q, Duan L, Estes JD, et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005; 434(7037): 1148-1152.
2. Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? Aids 2011; 25(7): 885-897.
3. Girard MP, Osmanov S, Assossou OM, Kieny MP. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine 2011; 29(37): 6191-6218.
4. Arien K, Jespers V, Vanham G. HIV sexual transmission and microbicides. Rev Med Virol 2011; 21: 110-133.
5. Jin F, Jansson J, Law M, et al. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. Aids 2010; 24(6): 907-913.
6. Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV- 1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9(2): 118-129.
7. Yu M, Vajdy M. Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes. Expert Opin Biol Ther 2010; 10(8): 1181-195.
8. Varghese B, Maher JE, Peterman TA, Branson BM, Steketee RW. Reducing the risk of sexual HIV transmission: quantifying the peract risk for HIV on the basis of choice of partner, sex act, and condom use. Sex Transm Dis 2002; 29(1): 38-43.
9. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA: the journal of the American Medical Association 2000; 283(9): 1167-1174.
10. De Cock KM, Fowler MG, Mercier E, et al. Prevention of motherto-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA: the journal of the American Medical Association 2000; 283(9): 1175-1182.
11. Piot P, Bartos M, Ghys PD, Walker N, Schwartlander B. The global impact of HIV/AIDS. Nature 2001; 410(6831): 968-973.
12. Gray RH, Wawer MJ, Brookmeyer R et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. The Lancet [S0140-6736(00)04331-2 pii;10.1016/S0140-6736(00)04331-2 doi]. 2001; 357(9263): 1149-53.
13. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191(9): 1403-1409.
14. Pope M, Haase AT. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 2003; 9(7): 847-852.
15. Abrahams MR, Anderson JA, Giorgi EE, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. Journal of Virology 2009; 83(8): 3556-3567.
16. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al. Envelopeconstrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004; 303(5666): 2019-2122.
17. Gottlieb GS, Heath L, Nickle DC, et al. HIV-1 variation before seroconversion in men who have sex with men: analysis of acute/early HIV infection in the multicenter AIDS cohort study. The Journal of infectious diseases 2008; 197(7): 1011-1015.
18. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America 2008; 105(21): 7552-7557.
19. Salazar-Gonzalez JF, Bailes E, Pham KT, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008; 82(8): 3952-3970.
20. Wolinsky SM, Wike CM, Korber BT, et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants [see comments]. Science. 1992; 255(5048): 1134-1137.
21. Zhang H, Tully DC, Hoffmann FG, et al. Restricted genetic diversity of HIV-1 subtype C envelope glycoprotein from perinatally infected Zambian infants. PLoS One 2010; 5(2): e9294.
22. Novella IS, Elena SF, Moya A, Domingo E, Holland JJ. Size of genetic bottlenecks leading to virus fitness loss is determined by mean initial population fitness. JVirol. 1995; 69(5): 2869-2872.
23. Domingo E, Escarmis C, Sevilla N, Moya A, Elena SF, Quer J, et al. Basic concepts in RNA virus evolution. FASEB J. 1996; 10(8): 859-864.
24. Muller HJ. The relation of recombination to mutational advance. MutatRes. 1964; 1: 2-9.
25. Quinones-Mateu ME. Is HIV-1 evolving to a less virulent (pathogenic) virus? Aids 2005; 19(15): 1689-1690.
26. Arien KK, Vanham G, Arts EJ. Is HIV-1 evolving to a less virulent form in humans? Nat Rev Microbiol. 2007; 5(2): 141-151.
27. Figdor CG, van Kooyk Y, Adema GJ. C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol 2002; 2(2): 77-84.
28. de Witte L, Nabatov A, Pion M, et al. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat Med 2007; 13(3): 367-371.
29. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol 2008; 8(6): 447-457.
30. Hladik F, Sakchalathorn P, Ballweber L, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007; 26(2): 257-270.
31. Merad M, Romani N, Randolph G. Langerhans cells at the interface of medicine, science, and industry. J Invest Dermatol. [Congresses]. 2008; 128(2): 251-255.
32. Miller CJ, Li Q, Abel K, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005; 79(14): 9217-9227.
33. Zhang ZQ, Wietgrefe SW, Li Q, et al. Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proceedings of the National Academy of Sciences of the United States of America 2004;101(15): 5640-5645.
34. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464(7286): 217-223.
35. Haase AT. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol 1999; 17: 625-656.
36. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse trasncriptase. Science 1988; 242: 1168-1171.
37. Nicolosi A, Correa Leite ML, Musicco M, Arici C, Gavazzeni G, Lazzarin A. The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology 1994; 5(6): 570-575.
38. UNAIDS. Report on the Global AIDS Epidemic. 2010.
39. Bomsel M, David V. Mucosal gatekeepers: selecting HIV viruses for early infection. Nat Med 2002; 8(2): 114-116.
40. Anderson DJ, Politch JA, Nadolski AM, et al. Targeting Trojan Horse leukocytes for HIV prevention. Aids 2010; 24(2): 163-187.
41. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med 1997; 3(1): 42-47.
42. Hubner W, Chen P, Del Portillo A, et al. Sequence of human immunodeficiency virus type 1 (HIV-1) Gag localization and oligomerization monitored with live confocal imaging of a replication-competent, fluorescently tagged HIV-1. J Virol 2007; 81(22): 12596-12607.
43. Sabatte J, Ceballos A, Raiden S, et al. Human seminal plasma abrogates the capture and transmission of human immunodeficiency virus type 1 to CD4+ T cells mediated by DCSIGN. JVirol [JVI.01079-07 pii;10.1128/JVI.01079-07 doi] 2007; 81(24): 13723-13734.
44. Munch J, Rucker E, Standker L, et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell [S0092-8674(07)01284-6 pii;10.1016/j.cell.2007.10.014 doi] 2007; 131(6): 1059-1071.
45. Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L. Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev 2005; 206: 306-335.
46. Cremel M, Berlier W, Hamzeh H, et al. Characterization of CCL20 secretion by human epithelial vaginal cells: involvement in Langerhans cell precursor attraction. J Leukoc Biol 2005; 78(1): 158-166.
47. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV- 1 coreceptors: roles in viral entry, tropism, and disease. AnnuRevImmunol 1999; 17: 657-700.
48. Abel K, Rocke DM, Chohan B, Fritts L, Miller CJ. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol 2005; 79(19): 12164-12172.
49. Burgener A, Rahman S, Ahmad R, et al. Comprehensive Proteomic Study Identifies Serpin and Cystatin Antiproteases as Novel Correlates of HIV-1 Resistance in the Cervicovaginal Mucosa of Female Sex Workers. J Proteome Res 2011; 10(11): 5139-5149.
50. Grant RM, Hamer D, Hope T, et al. Whither or wither microbicides? Science 2008; 321(5888): 532-534.
51. Abdool KQ, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. [science.1193748 pii;10.1126/science.1193748 doi]. 2010; 329(5996): 1168-1174.
52. Prevention CfDCa. HIV Surveillance Report 2009. http://wwwcdcgov/hiv/topics/surveillance/resources/reports/2011; 21.
53. Canada PHAo. HIV and AIDS in Canada, Surveillance Report December 31, 2009. Surveillance and Risk Assessment Division, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada. 2010.
54. Veldhuijzen NJ, Ingabire C, Luchters S, et al. Anal intercourse among female sex workers in East Africa is associated with other high-risk behaviours for HIV. Sex Health 2011; 8(2): 251-254.
55. Lane T, Pettifor A, Pascoe S, Fiamma A, Rees H. Heterosexual anal intercourse increases risk of HIV infection among young South African men. Aids 2006; 20(1): 123-125.
56. Kalichman SC, Simbayi LC, Cain D, Jooste S. Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa. Sex Transm Infect 2009; 85(6): 411-415.
57. Hladik F, Dezzutti CS. Can a topical microbicide prevent rectal HIV transmission? PLoS Med 2008; 5(8): e167.
58. Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008; 5(2): e28.
59. McGowan I. Rectal microbicides: can we make them and will people use them? AIDS Behav 2011; 15 Suppl 1: S66-S71.
60. Mowat AM, Viney JL. The anatomical basis of intestinal immunity. Immunol Rev 1997 Apr; 156: 145-166.
61. Cerf-Bensussan N, Guy-Grand D. Intestinal intraepithelial lymphocytes. Gastroenterol Clin North Am 1991; 20(3): 549-576.
62. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. NatRevMicrobiol [10.1038/nrmicro729 doi]. 2003; 1(1): 25-34.
63. Veazey RS, DeMaria M, Chalifoux LV, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998; 280(5362): 427-431.
64. Ribeiro Dos Santos P, Rancez M, et al. Rapid dissemination of SIV follows multisite entry after rectal inoculation. PLoS One 2011; 6(5): e19493.
65. Cranage M, Sharpe S, Herrera C, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med 2008; 5(8): e157; discussione.
66. Fuchs EJ, Lee LA, Torbenson MS, et al. Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J Infect Dis 2007; 195(5): 703-710.
67. Singer R, Derby N, Rodriguez A, et al. The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. J Virol 2011; 85(11): 5504-5512.
68. Patterson BK, Landay A, Siegel JN, et al. Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol 2002; 161(3): 867-873.
69. Ganor Y, Bomsel M. HIV-1 transmission in the male genital tract. Am J Reprod Immunol 65(3): 284-291.
70. Donoval BA, Landay AL, Moses S, et al. HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am J Clin Pathol 2006; 125(3): 386-391.
71. McCoombe SG, Short RV. Potential HIV-1 target cells in the human penis. Aids. 2006; 20(11): 1491-1495.
72. Szabo R, Short RV. How does male circumcision protect against HIV infection? Bmj 2000; 320(7249): 1592-1594.
73. Kigozi G, Wawer M, Ssettuba A, et al. Foreskin surface area and HIV acquisition in Rakai, Uganda (size matters). Aids 2009; 23(16): 2209-2213.
74. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2(11): e298.
75. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomized controlled trial. Lancet 2007 Feb 24; 369(9562): 643-656.
76. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369(9562): 657-666.
77. Edwards S, Carne C. Oral sex and the transmission of viral STIs. Sex Transm Infect 1998; 74(1): 6-10.
78. Coovadia HM, Coutsoudis A. HIV, infant feeding, and survival: old wine in new bottles, but brimming with promise. Aids 2007; 21(14): 1837-1840.
79. Malamud D, Wahl SM. The mouth: a gateway or a trap for HIV? Aids 2010; 24(1): 5-16.
80. Shugars DC, Wahl SM. The role of the oral environment in HIV-1 transmission. J Am Dent Assoc 1998; 129(7): 851-858.
81. Drannik AG, Henrick BM, Rosenthal KL. War and peace between WAP and HIV: role of SLPI, trappin-2, elafin and ps20 in susceptibility to HIV infection. Biochem Soc Trans 2011; 39(5): 1427-1432.
82. Ma G, Greenwell-Wild T, Lei K, et al. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 2004; 200(10): 1337-1346.
83. Shugars DC. Endogenous mucosal antiviral factors of the oral cavity. J Infect Dis 1999; 179 Suppl 3: S431-S435.
84. Kazmi SH, Naglik JR, Sweet SP, et al. Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin Vaccine Immunol 2006; 13(10): 1111-1118.
85. Herzberg MC, Vacharaksa A, Gebhard KH, Giacaman RA, Ross KF. Plausibility of HIV-1 Infection of Oral Mucosal Epithelial Cells. Adv Dent Res 2011; 23(1): 38-44.
86. Diamond G, Beckloff N, Weinberg A, Kisich KO. The roles of antimicrobial peptides in innate host defense. Curr Pharm Des 2009; 15(21): 2377-2392.
87. Quinones-Mateu ME, Lederman MM, Feng Z, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. Aids 2003; 17(16): F39-F48.
88. Sun L, Finnegan CM, Kish-Catalone T, et al. Human betadefensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol 2005; 79(22): 14318-14329.
89. Tugizov SM, Herrera R, Veluppillai P, Greenspan D, Soros V, Greene WC, et al. HIV is inactivated after transepithelial migration via adult oral epithelial cells but not fetal epithelial cells. Virology 2011; 409(2): 211-222.
90. Liu L, Wang L, Jia HP, et al. Structure and mapping of the human beta-defensin HBD-2 gene and its expression at sites of inflammation. Gene 1998; 222(2): 237-244.
91. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. [see comments.]. N Engl J Med 2002; 347(15): 1151-1160.
92. Dale BA, Kimball JR, Krisanaprakornkit S, et al. Localized antimicrobial peptide expression in human gingiva. J Periodontal Res 2001; 36(5): 285-294.
93. Gupta S, Ghosh SK, Scott ME, et al. Fusobacterium nucleatumassociated beta-defensin inducer (FAD-I): identification, isolation, and functional evaluation. J Biol Chem 2010 Nov 19; 285(47): 36523-36531.